Indaptus Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Indaptus Therapeutics R&D Spending Growth & History (INDP)
Indaptus Therapeutics's r&d spending was $9.3M for fiscal 2025.
View full Indaptus Therapeutics company overviewIndaptus Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.3M | $2.1M | +28.82% |
| 2024 | 2024-12-31 | $7.3M | −$370,610 | −4.86% |
| 2023 | 2023-12-31 | $7.6M | $1.3M | +20.51% |
| 2022 | 2022-12-31 | $6.3M | $3.8M | +150.66% |
| 2021 | 2021-12-31 | $2.5M | −$131,864 | −4.97% |
| 2020 | 2020-12-31 | $2.7M | — | — |
Indaptus Therapeutics quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $363,127 | −$1.8M | −83.24% |
| Q1 2026 | 2026-03-31 | $491,134 | −$2.3M | −82.53% |
| Q4 2025 | 2025-12-31 | $2.8M | $365,337 | +14.73% |
| Q3 2025 | 2025-09-30 | $1.5M | $51,686 | +3.53% |
| Q2 2025 | 2025-06-30 | $2.2M | $453,141 | +26.44% |
| Q1 2025 | 2025-03-31 | $2.8M | $1.2M | +76.66% |
| Q4 2024 | 2024-12-31 | $2.5M | $445,311 | +21.89% |
| Q3 2024 | 2024-09-30 | $1.5M | −$760,651 | −34.16% |
| Q2 2024 | 2024-06-30 | $1.7M | $233,488 | +15.77% |
| Q1 2024 | 2024-03-31 | $1.6M | −$288,758 | −15.36% |
| Q4 2023 | 2023-12-31 | $2.0M | $122,794 | +6.42% |
| Q3 2023 | 2023-09-30 | $2.2M | $617,134 | +38.34% |
| Q2 2023 | 2023-06-30 | $1.5M | −$25,680 | −1.70% |
| Q1 2023 | 2023-03-31 | $1.9M | $582,802 | +44.93% |
| Q4 2022 | 2022-12-31 | $1.9M | $967,200 | +102.39% |
| Q3 2022 | 2022-09-30 | $1.6M | $911,880 | +130.70% |
| Q2 2022 | 2022-06-30 | $1.5M | $1.1M | +285.09% |
| Q1 2022 | 2022-03-31 | $1.3M | $807,377 | +164.86% |
| Q4 2021 | 2021-12-31 | $944,640 | — | — |
| Q3 2021 | 2021-09-30 | $697,674 | −$652,161 | −48.31% |
| Q2 2021 | 2021-06-30 | $391,118 | −$883,882 | −69.32% |
| Q1 2021 | 2021-03-31 | $489,721 | — | — |
| Q3 2020 | 2020-09-30 | $1.3M | — | — |
| Q2 2020 | 2020-06-30 | $1.3M | — | — |
Indaptus Therapeutics r&d spending trends
Over the last five fiscal years, Indaptus Therapeutics's r&d spending increased from $2.7M to $9.3M, a change of $6.7M. The latest reported quarter, Q2 2026, shows $363,127.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Indaptus Therapeutics source filings ↗